Fujita Health University and Boyalife Group Partner to Build International Regenerative Medicine Research Center in Japan

2018-03-27T14:38:52-07:00 11月 15, 2017|

On November 11, 2017, a delegation from Fujita Health University (FHU) visited Boyalife Group to sign a formal cooperation agreement to jointly build a large, international regenerative medicine research center in Japan. The agreement was signed by Dr. Hoshinaga, president of FHU, and Dr. Chun Ming Guo, vice president of Boyalife. The signing ceremony was also attended by Professor Kuniaki Saito and Naoki Yamamoto (both from FHU), Hiroshi Sugisaki (minister of the Planning Department), Professor Hiroshi Kawamoto and Yasuo Miura (both from Kyoto University), Dr. Xiaochun Xu (president of Boyalife), Yishu Li (chairman of Boyalife), Mou Wang (vice president of Boyalife) and Hairong Xiao (assistant president of Boyalife).

Yishu Li (far right), the chairman of Boyalife, received the delegation led by Dr. Hoshinaga (third from right)

Dr. Xu opened the ceremony with a speech welcoming President Hoshinaga, and also laid out his vision for mutual cooperation in the field of regenerative medicine in the future.

“The treatment of serious diseases will undergo substantial reform in the future, and cell therapy technology represents the future of medicine,” said Dr. Xu. ““Boyalife has developed broad techniques and advanced clinical applications in the field of stem cell automation and point-of-care systems. A number of the world’s leading medical organizations have been working with us to build a modern, next-generation biomanufacturing and automated cell therapy center. The center that we will jointly build will be Japan’s first clinical research center featuring automated techniques in the field of regenerative medicine.”

The Fujita-Boyalife International Research Center for Regenerative Medicine will include: (1) an advanced international medical health center; (2) a high-end automated cell manufacturing platform complying with cGMP standards; (3) a fully-automated, clinical biological resource library; and (4) advanced cell therapy clinical research facilities. Both parties will study induced pluripotent stem (iPS) cells, and will research different kinds of stem cells and immune cells.

“The Fujita-Boyalife International Research Center for Regenerative Medicine will be completed next year. We wish it a great success and numerous achievements in Japan,” said President Hoshinaga.

Ye Zhao, director of National Life Science Park Wuxi Mashan China, also expressed his best wishes for mutual cooperation during the signing ceremony. He extended full support for cooperation between both parties on behalf of the Wuxi Government, and wished the project great success.

Dr. Chunming Guo, vice president of Boyalife (left), and Dr. Hoshinaga, FHU (right), signed the agreement on behalf of the two parties

Japan has long been a global leader in medical technology. Established in 1964, FHU ranks number one in academics in a comprehensive ranking of Japanese private medical colleges. As mentioned by Professor Hoshinaga, FHU established Japan’s largest private hospital. It is also Japan’s largest teaching and internship hospital employing the most advanced medical devices. Patients will benefit from this Fujita-Boyalife collaboration. Dr. Hoshinaga has visited Boyalife numerous times in the past. During the signing ceremony, he commented, “This is my eighth time leading a delegation to Boyalife, and because of our long-standing relationship, we expect great cooperation. We sincerely hope that, as a result of this ceremony, we can now introduce Boyalife’s advanced techniques and ideas to Japan’s medical community through FHU.”

As the leading biomedical enterprise in China covering all facets of the stem cell industry, Boyalife has significant resources, including automation equipment and technical platforms, including the AXP®/BioArchive® automated stem cell separation and storage system, the MXP® system that can separate bone marrow stem cells within 50-60 minutes, and the CAR-TXpress automated platform for manufacturing CAR-T cells with high efficiency and lower cost. Boyalife also owns the second largest stem cell banking operation in China, and has participated in dozens of stem cell clinical studies involving more than 1,000 patients suffering from an array of serious diseases. Boyalife has established many independent and cooperative R&D organizations around the world. The new R&D center being established in Japan as a result of the Boyalife/FHU collaboration will advance regenerative medicine and cell therapy clinical technology for both parties.